Showing 2251-2260 of 5696 results for "".
- AffaMed Therapeutics Announces Positive Topline Results from Real-World Study in China Evaluating Dextenza in Patients after Cataract Surgeryhttps://modernod.com/news/affamed-therapeutics-announces-positive-topline-results-from-real-world-study-in-china-evaluating-dextenza-in-patients-after-cataract-surgery/2481932/AffaMed Therapeutics announced positive topline results from the real-world study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain followi
- AbbVie Enters into Option Agreement with Aldeyra Therapeutics for License to Develop and Commercialize Reproxalaphttps://modernod.com/news/abbvie-enters-into-option-agreement-with-aldeyra-therapeutics-for-license-to-develop-and-commercialize-reproxalap/2481929/Aldeyra Therapeutics announced that it has entered into an exclusive option agreement with AbbVie in which AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the US, and an exclusive license to develop, manufacture, and comme
- SpyGlass Pharma Initiates Phase 1/2 Clinical Trial of its Intraocular Drug Delivery Platformhttps://modernod.com/news/spyglass-pharma-initiates-phase-12-clinical-trial-of-its-intraocular-drug-delivery-platform/2481924/SpyGlass Pharma announced the initiation of a phase 12 clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant cataracts. The SpyGlass
- Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophyhttps://modernod.com/news/annexon-receives-prime-designation-from-the-ema-for-anx007-for-the-treatment-of-geographic-atrophy/2481911/Annexon announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The EMA granted this designation based on the phase 2 ARCHER
- SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Diseasehttps://modernod.com/news/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/2481894/SpliceBio has announced the signing of an exclusive collaboration and licensing agreement with Spark Therapeutics to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. Under the terms of
- Zeiss and Boehringer Ingelheim Partner to Develop Early Detection of Eye Diseases and Prevent Vision Losshttps://modernod.com/news/zeiss-and-boehringer-ingelheim-partner-to-develop-early-detection-of-eye-diseases-and-prevent-vision-loss/2481859/Zeiss Medical Technology and Boehringer Ingelheim announced a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with eye diseases. The partnership aims to bring togeth
- Melt Pharmaceuticals Announces Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technologyhttps://modernod.com/news/melt-pharmaceuticals-announces-development-and-license-agreement-with-catalent-for-its-zydis-fast-dissolve-technology/2481857/Melt Pharmaceuticals, a former subsidiary of Harrow Health, announced it has entered into an exclusive development and license agreement with Catalent in which Melt will utilize Catalent’s proprietary Zydis orally disintegrating tablet (ODT) fast-dissolve technology with MELT
- Oculus Announces Parnership with Luvo to Offer New IPL and RF Devices for the US Ophthalmic Markethttps://modernod.com/news/oculus-announces-parnership-with-luvo-to-offer-new-ipl-and-rf-devices-for-the-us-ophthalmic-market/2481853/Oculus has announced a strategic partnership with Luvo to bring new specialty care devices to the US optometry and ophthalmology market. As part of the deal, Oculus is launching the Luvo Lucent and Darwin with Intense Pulse Light and Radio Frequency therapy, which are designed to e
- Otsuka and ShapeTX Collaborate to Develop AAV Gene Therapies for Ocular Diseaseshttps://modernod.com/news/otsuka-and-shapetx-collaborate-to-develop-aav-gene-therapies-for-ocular-diseases/2481832/Otsuka Pharmaceutical and ShapeTX, a programmable medicine company using artificial intelligence (AI) and RNA to combat genetic diseases, announced a multitarget collaboration to develop intravitreally delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional t
- Study Finds Role of Biosynthetic Fatty Acid Pathway Insufficiencies in Age-Related Macular Degenerationhttps://modernod.com/news/study-finds-role-of-biosynthetic-fatty-acid-pathway-insufficiencies-in-age-related-macular-degeneration/2481831/LSU Health Sciences Center announced the publication of findings that suggest that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential. The research was led by Nicolas Bazan,